Neuroblastoma accounts for >10% of all cancer-related deaths in the paediatric population. Among patients with relapse of high-risk neuroblastoma, 5-year overall survival is <20%. Now, a phase I/II trial has revealed the promising activity of GD2-CART01, an autologous T cell product expressing both a GD2-directed chimeric antigen receptor (CAR) with 4-1BB and CD28 co-stimulatory domains and an inducible caspase 9-based (iC9) safety switch, in this setting.